Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference32 articles.
1. Use of sodium-glucose cotransporter-2 inhibitors in clinical practice for heart failure prevention and treatment: beyond type 2 diabetes. A narrative review;Rao;Adv Ther.,2022
2. Cardiovascular and renal outcomes with empagliflozin in heart failure;Packer;N. Engl. J. Med.,2020
3. National Burden of heart failure events in the United States, 2006 to 2014;Jackson;Circ. Heart Fail.,2018
4. Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure;Faridi;J. Am. Coll. Cardiol.,2022
5. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials;Lytvyn;Circulation,2017
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data;Diabetes, Obesity and Metabolism;2024-08-07
2. General physicians' perspectives on SGLT2 inhibitors for heart failure;Internal Medicine Journal;2024-07-03
3. Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia;Frontiers in Pharmacology;2023-06-05
4. Good for your heart and safe for your toes: a patient-level meta-analysis of DAPA-HF and DELIVER;European Heart Journal;2023-05-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3